Argenx (ARGX) said Monday that it has discontinued a phase 3 study of its therapy subcutaneously administered efgartigimod in adults with moderate to severe thyroid eye disease.
The decision was prompted by a recommendation from an independent monitoring committee to stop the trials because of futility after a review of data, the company said.
Argenx Chief Medical Officer Luc Truyen said the studies of the trial data "did not meet our desired outcome."
Thyroid eye disease is an autoimmune condition that can lead to the loss of vision.
Shares of the company were down nearly 6% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments